# A Study to Evaluate Persistence of Hepatitis B Antibodies, Immunogenicity and Safety of Engerix™-B Kinder Challenge Dose, in Adolescents Vaccinated With Four Doses of Infanrix™ Hexa During Infancy

> **NCT02798952** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 302 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** Engerix-B Kinder

## Key facts

- **NCT ID:** NCT02798952
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-23
- **Primary completion:** 2017-07-05
- **Final completion:** 2017-07-05
- **Target enrollment:** 302 (ACTUAL)
- **Last updated:** 2020-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02798952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02798952, "A Study to Evaluate Persistence of Hepatitis B Antibodies, Immunogenicity and Safety of Engerix™-B Kinder Challenge Dose, in Adolescents Vaccinated With Four Doses of Infanrix™ Hexa During Infancy". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02798952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*